FDA 21 CFR Part 11

FDA 21 CFR Part 11 is one of the most consequential regulations in the life sciences and pharmaceutical industries. Issued by the U.S. Food and Drug Administration (FDA), it establishes the criteria under which electronic records and electronic signatures are considered trustworthy, reliable, and equivalent to paper records and handwritten signatures.

As organizations across pharma, biotechnology, medical devices, contract research, and manufacturing accelerate their digital transformation, understanding and achieving Part 11 compliance has never been more critical. Non-compliance can result in Form 483 observations, Warning Letters, consent decrees, import alerts, or product recalls, all of which carry substantial reputational and financial consequences.

This white paper provides a comprehensive reference for quality, regulatory, compliance, and IT professionals responsible for implementing or auditing Part 11-compliant systems. It covers the regulatory background, the full scope of Part 11 requirements for both closed and open systems, practical implementation guidance, common pitfalls, and how a validated cloud-native eQMS platform can simplify ongoing compliance.